CLAIMS

A peptide derivative represented by the general formula
 or a salt thereof:

$$Z-(CH_2)_n-CO-NH-Leu-Ile-Gly-AA_1-AA_2-CO-R$$
 (I)

wherein Z represents an aryl group which may or may not have a substituent or a heteroaryl group which may or may not have a substituent; n represents 0, 1 or 2; AA_1-AA_2 represents Lys-Val or Arg-Leu; and R represents -OH or -NH₂.

- 2. The peptide derivative or a salt thereof according to claim

 1, where Z represents an aryl group which may or may not have
 a halogen atom, a lower alkyl group, a lower alkoxyl group, phenyl
 group, a phenyl-lower alkyl group or nitro group as the
 substituent or a heteroaryl group which may or may not have a
 halogen atom, a lower alkyl group, a lower alkoxyl group, phenyl
 group, a phenyl-lower alkyl group or nitro group as the
 substituent.
- The peptide derivative or a salt thereof according to claim 1 or 2, where the aryl group is phenyl group or naphthyl group; and the heteroaryl group is furyl group, thienyl group, pyridyl group or quinolyl group.
- 4. A pharmaceutical composition comprising a peptide derivative or a salt thereof according to any one of claims 1 to 3, and a pharmaceutically acceptable carrier thereof.





- 5. The pharmaceutical composition according to claim 4, which is a PAR-2-activating agent.
- 6. The pharmaceutical composition according to claim 4 or 5, which is a prophylactic and therapeutic agent of the decrease of saliva secretion, the decrease of lacrimal fluid secretion or gastrointestinal disorders.
- 7. The pharmaceutical composition according to any one of claims 4 to 6, where the pharmaceutical composition is a prophylactic and therapeutic agent of dysfunction of masticatory, dysphagia, dysgeusia (taste disorder), ozostomia, intra-oral cavity dysphoria, intra-oral cavity infections, intra-oral cavity inflammations, dry eye, ectocornea detachment, keratitis, corneal ulcer, conjunctivitis, stomach ulcer, duodenal ulcer, gastritis, diarrhea, enteritis or Sjogren's syndrome.